Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Solvay Pharmaceuticals
With
Bristol-Myers Squibb
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18-70 years and BMI ≥27 with type 2 diabetes who have been treated with diet and exercise only or with half maximal or greater metformin or sulfonylurea monotherapy (stable dose for at least three months), but who remained inadequately controlled (HbA1c \>7% and HbA1c\<10%).
You may not be if
Pregnancy
Anti-diabetic medications other than baseline metformin or sulfonylurea monotherapy
History of myocardial infarction in the prior six months/ History of heart failure defined as New York Heart Association Functional Class I, II, III or IV/ History of symptomatic arrhythmia
Active hepatic disease/ Any documented muscle disease
History of multiple sclerosis/ Baseline history of tremors, ataxia, anxiety or dizziness
Seizures within the last year, stroke, and transient ischemic attack/ Known history of schizophrenia, dementia, or bipolar disorder as defined by DSM IV criteria.
Currently depressed subjects or a CES-D score greater or equal to 16 at the screening visit or at baseline (Day 1)/ History of suicide attempt or ideation
Previous history of surgical procedures for weight loss (e.g. stomach stapling, bypass)/ Weight loss greater than 5 kg in the prior 3 months
Clareo Health | BMS-646256 in Obese and Overweight Type 2 Diabetics
